Dai-ichi Life Insurance Company’s AstraZeneca AZN Stock Holding History

Dai-ichi Life Insurance Company’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-7,210	Closed	-$866K	–	538
2021 Q3	$866K	Buy	+7,210	New	+$839K	0.01%	433

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Dai-ichi Life Insurance Company's AZN Position: Q4 2021 in Review

Dai-ichi Life Insurance Company sold out of AstraZeneca (AZN) in Q4 2021, closing a stake of 7,210 shares — an estimated $866K sold.

Dai-ichi Life Insurance Company first reported a position in AZN in Q3 2021 and held it in 1 quarter. The position peaked at $866K in Q3 2021. 950 funds tracked by Wall St. Rank hold AZN as of Q4 2021.

Dai-ichi Life Insurance Company reported no remaining AstraZeneca position as of Q4 2021 after selling out during the quarter.
Dai-ichi Life Insurance Company sold 7,210 AstraZeneca shares in Q4 2021, an estimated $866K.
Dai-ichi Life Insurance Company first reported a position in AstraZeneca in Q3 2021 and held it in 1 quarter.
Dai-ichi Life Insurance Company's AstraZeneca position peaked at $866K in Q3 2021.
950 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2021.

Based on Dai-ichi Life Insurance Company's 13F filing for Q4 2021, filed 11 Feb 2022.